Drug Approval | July 27, 2025
Alembic Pharmaceuticals announces USFDA final approval for Carbamazepine ER Tablets USP
Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug
Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug
Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of Ovarian Cancer, AIDS-Related Kaposi's Sarcoma, and Multiple Myeloma
Amlodipine and Atorvastatin tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin
Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
Carbamazepine Tablets USP, 200 mg have an estimated market size of US$ 32 million for twelve months ending December 2024 according to IQVIA
Pantoprazole Sodium for Injection, 40 mg/vial (Single-Dose Vial) have an estimated market size of US$ 48 million for twelve months ending December 2024 according to IQVIA
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti Tablets
Divalproex Sodium Delayed-Release Capsules USP, 125 mg have an estimated market size of US$ 61.1 million for twelve months ending September 2024 according to IQVIA
Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander
Subscribe To Our Newsletter & Stay Updated
